Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Agilent Technologies Inc. and Synthego Corp. sparred Friday over whether Agilent patents related to a key component of the ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

The sequence contained a promising new genetic tool for modifying DNA, a CRISPR. Editas Medicine, a Massachusetts-based ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line ...

The company’s first approved product, CASGEVY, is a groundbreaking CRISPR/Cas9 gene-edited therapy for sickle cell disease and transfusion-dependent beta-thalassemia. This historic approval in ...

By 2028, Crispr Therapeutics could be a billion dollar revenue company through Casgevy alone. This more than justifies the current market cap in my view (don't forget the $1.6bn of cash either ...

In fact, bioethicists warned about such “frivolous” uses of CRISPR a decade ago when the technology was in its infancy. The company’s glowing rabbits will be an initial test to see how ...